Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL2354846 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL1728893 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL4920513 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL7537653 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL5679533 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL703430 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL509509 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL723498 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL2392102 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL37333 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1748 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111978331-B | Preparation method of FLT3 and FGFR kinase inhibitor | 上海再极医药科技有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-116041374-A | Diagnosis and treatment integrated nano material for photo-activated tumor chemophotodynamic therapy and preparation method and application thereof | 中南大学 | 2023-05-02 | — | — | CN | claimed |
| CN-111808109-B | Pyridazine quinoxaline diamine Schiff base cobalt ion fluorescent probe and preparation method thereof | 南京林业大学 | 2022-03-25 | — | — | CN | claimed |
| CN-112876409-A | Synthesis method of 2- (5-bromo-6-methoxypyridine-2-yl) acetonitrile and derivatives thereof | 都创(上海)医药科技股份有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-111808109-A | Pyridazine quinoxaline diamine Schiff base cobalt ion fluorescent probe and preparation method thereof | 南京林业大学 | 2020-10-23 | — | — | CN | claimed |
| CN-108503643-B | Process for the preparation of protease inhibitors | 泉州易初生物医药科技有限公司 | 2020-09-15 | — | — | CN | claimed |
| CN-108947990-A | A kind of preparation method of benzothiophenes | 成都苑东生物制药股份有限公司 | 2018-12-07 | — | — | CN | claimed |
| WO-2024149261-A1 | INHIBITOR OF COMPLEMENT FACTOR B | 南京正大天晴制药有限公司 | 2024-07-18 | — | — | WO | disclosed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | FORMA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4400499-A1 | GLUTARIMIDE COMPOUND AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118354999-A | Pyridazine-1 (6H) -6-oxo compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-4863904-A | Dipeptides as renin inhibitors | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0269968-A2 | Heteroaromatic amine derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-06-08 | — | — | EP | disclosed |
| EP-0224794-A2 | Cyclic amine derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1987-06-10 | — | — | EP | disclosed |
| EP-0181110-A2 | Histidine derivatives as renin inhibitors | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0161599-A2 | Benzazepine derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-11-21 | — | — | EP | disclosed |
| US-4503046-A | 1-Nitro-aminoglycoside derivatives, pharmaceutical compositions containing them and such derivatives for use as pharmaceuticals | SANDOZ LTD. (CH) | 1985-03-05 | — | — | US | disclosed |
| EP-0072351-A1 | Aminoglycoside derivatives, processes for their production, pharmaceutical compositions containing them and such derivatives for use as pharmaceuticals | SANDOZ AG (CH) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | TSHR 4153/4885TDP1 548/4885TP53 1161/4885 |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | USP1, USP2, USP3 | TSHR 3872/4885TDP1 691/4885TP53 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.